Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The neuronal ceroid lipofuscinoses (NCLs)
- Autofluorescence in brain tissue in NCL
- The neuronal ceroid lipofuscinoses
- Homogeneous groups in the heterogeneous NCLs
- Three major forms of NCL
- Clinical features of NCL infantile
- Infantile NCL (CLN1) - Santavuori-Haltia disease
- Jansky-Bielschowsky disease
- Late infantile NCL (CLN2)
- Batten-Spielmeyer-Vogt
- Juvenile NCL (CLN3) Batten disease
- Electron microscopy to subclassify forms of NCL
- Atypical forms
- Different forms of NCL
- Rare variants of NCL
- CLN1/PPT1: palmitoyl-protein thioesterase
- Palmitoyl-protein thioesterase
- PPT activity in lymphoblasts
- Structure of palmitoyl protein thioesterase (CLN1)
- Space filling model of the CLN1 enzyme
- Active site of palmitoyl-protein thioesterase
- Palmitate analog in binding pocket of PPT1
- Missense mutations in PPT
- Arg122Trp - common Finnish mutation
- Gln177Asp mutation in late infantile NCL
- Thr75Pro and Asp79Gly mutations
- CLN2 Tripeptidyl peptidase I
- Structure of tripeptidyl peptidase-1 (CLN2)
- CLN3/Battenin
- Common mutation in juvenile NCL
- CLN4/DNAJC5: cysteine string protein
- CLN5
- CLN6
- CLN7/MFSD8
- CLN8
- Other rare forms of NCL
- Neurodegeneration in the NCLs
- Neuronal dropout in a mouse model of NCL
- Mechanisms of neurodegeneration
- Apoptotic neurons in a mouse model of NCL
- Mechanisms of selective neurodegeneration
- Proteinaceous storage material
- Defects in lysosomal pH regulation
- Treatment approaches for the NCLs
- Lysosomal enzyme trafficking
- NCL clinical trials
- Treatment development approaches for the NCLs
- Natural and engineered animal models of NCLs
- Summary of progress in the NCLs
- Thank you!
Topics Covered
- Clinical features of the neuronal ceroid lipofuscinoses
- Genetics
- Genotype/phenotype correlations
- Protein epidemiology
- Mechanisms of neurodegeneration
- Treatment approaches
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hofmann, S. (2016, July 27). The neuronal ceroid lipofuscinoses [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/WWQV1150.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sandra Hofmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The neuronal ceroid lipofuscinoses
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello,
my name is Sandra Hofmann,
and I'm a professor in
the Department of Internal
Medicine at the University
of Texas Southwestern
Medical Center in Dallas.
The title of my presentation is
The Neuronal Ceroid Lipofuscinoses.
0:17
The neuronal ceroid lipofuscionses,
or NCLs, as I will refer to them
throughout the rest of my
talk, are a group of inherited
metabolic disorders of
children characterized
by progressive blindness,
progressive mental retardation
and motor deficits, seizures, and
autosomal recessive inheritance,
such that multiple
siblings may be affected.
Auto fluorescent storage
material accumulates
in the brain and other tissues.
The disorder may be diagnosed when
skin, lymphocytes, or brain tissue
from an affected individual
are sectioned from microscopy
and the unstained sections are
placed under fluorescent light
and examined under a microscope,
as shown in the next slide.
1:05
The upper panels of this slide
show different regions of NCL brain
tissue, such as cortex,
hippocampus, pons, and cerebellum,
showing the bright
green autofluorescence,
which is not present in normal
tissue in the lower panels.
1:23
The name, neuronal
ceroid lipofuscinoses
was coined in 1968
by Zeman and Dyken
to distinguish certain patients
from those with Tay-Sachs disease,
which shares a similar phenotype.
This was at a time when the
enzymatic basis of Tay-Sachs
first became known.
The name comes from
first, the observation
that neurons are strongly affected.
The symptoms of the disease
are almost entirely related
to central nervous
system dysfunction,
although the autofluorescence
can be found throughout the body.
The cerebral cortex and hippocampus
are most profoundly affected.
Ceroid is a term pathologists use
to refer to waxy pigments seen
in pathologic states.
Lipofusion is the normal
yellow-brown pigment
seen in all tissues during
the normal course of aging.
It is believed to consist of the
indigestible remnants of organelles
and cellular debris that
accumulates over a lifetime.